|
1
|
Grönberg H: Prostate cancer epidemiology.
Lancet. 361:859–864. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hsing AW and Devesa SS: Trends and
patterns of prostate cancer: What do they suggest? Epidemiol Rev.
23:3–13. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Roddam AW, Hamdy FC, Allen NE and Price
CP: UK Prostate Cancer Risk Management Programme: The impact of
reducing the prostate-specific antigen threshold and including
isoform reflex tests on the performance characteristics of a
prostate-cancer detection programme. BJU Int. 100:514–517. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Müntener M, Kunz U, Eichler K, Puhan M,
Schmid DM, Sulser T and Strebel RT: Lowering the PSAthreshold for
prostate biopsy from 4 to 2.5 ng/ml: Influence on cancer
characteristics and number of men needed to biopt. Urol Int.
84:141–146. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shao YH, Albertsen PC, Roberts CB, Lin Y,
Mehta AR, Stein MN, DiPaola RS and Lu-Yao GL: Risk profiles and
treatment patterns among men diagnosed as having prostate cancer
and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern
Med. 170:1256–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Feldman BJ and Feldman D: The development
of androgen-independent prostate cancer. Nat Rev Cancer. 1:34–45.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scher HI and Sawyers CL: Biology of
progressive, castration-resistant prostate cancer: Directed
therapies targeting the androgen-receptor signaling axis. J Clin
Oncol. 23:8253–8261. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Han M, Partin AW, Piantadosi S, Epstein JI
and Walsh PC: Era specific biochemical recurrence-free survival
following radical prostatectomy for clinically localized prostate
cancer. J Urol. 166:416–419. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hurwitz MD, Schultz D, Richie JP, Wein AJ,
Whittington R, Malkowicz SB and D'Amico AV: Radical prostatectomy
for high-gradeprostate cancer. Urology. 68:367–370. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Grossmann ME, Huang H and Tindall DJ:
Androgen receptor signaling in androgen refractory prostate cancer.
J Natl Cancer Inst. 93:1687–1697. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, et
al: Docetaxel plus predonisone or mitoxantrone plus predonisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
predonisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamura K, Furihata M, Tsunoda T, Ashida S,
Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, et al:
Molecular features of hormone-refractory prostate cancer cells by
genome-wide gene expression profiles. Cancer Res. 67:5117–5125.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Satake H, Tamura K, Furihata M, Anchi T,
Sakoda H, Kawada C, Iiyama T, Ashida S and Shuin T: The
ubiquitin-like molecule interferon-stimulated gene 15 is
overexpressed in human prostate cancer. Oncol Rep. 23:11–16.
2010.PubMed/NCBI
|
|
15
|
Anchi T, Tamura K, Furihata M, Satake H,
Sakoda H, Kawada C, Kamei M, Shimamoto T, Fukuhara H, Fukata S, et
al: SNRPE is involved in cell proliferation and progression of high
grade prostate cancer through the regulation of androgen receptor
expression. Oncol Lett. 3:264–268. 2012.PubMed/NCBI
|
|
16
|
Yamamoto A, Nagano T, Takehara S, Hibi M
and Aizawa S: Shisa promotes head formation through the inhibition
of receptor protein maturation for the caudalizing factors, Wnt and
FGF. Cell. 120:223–235. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nagano T, Takehara S, Takahashi M, Aizawa
S and Yamamoto A: Shisa2 promotes the maturation of somatic
precursors and transition to the segmental fate in Xenopus embryos.
Development. 133:4643–4654. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto H, Oue N, Sato A, Hasegawa Y,
Yamamoto H, Matsubara A, Yasui W and Kikuchi A: Wnt5a signaling is
involved in the aggressiveness of prostate cancer and expression of
metalloproteinase. Oncogene. 29:2036–2046. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thiele S, Rauner M, Goettsch C, Rachner
TD, Benad P, Fuessel S, Erdmann K, Hamann C, Baretton GB, Wirth MP,
et al: Expression profile of WNT molecules in prostate cancer and
its regulation by aminobisphosphonates. J Cell Biochem.
112:1593–1600. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamamoto H, Kitadai Y, Yamamoto H, Oue N,
Ohdan H, Yasui W and Kikuchi A: Laminin gamma2 mediates
Wnt5a-induced invasion of gastric cancer cells. Gastroenterology.
137:242–252. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hanaki H, Yamamoto H, Sakane H, Matsumoto
S, Ohdan H, Sato A and Kikuchi A: An anti-Wnt5a antibody suppresses
metastasis of gastric cancer cells in vivo by inhibiting
receptor-mediated endocytosis. Mol Cancer Ther. 11:298–307. 2012.
View Article : Google Scholar : PubMed/NCBI
|
